Skip to main content
Sudeep Pharma Limited logo

Sudeep Pharma Limited — Investor Relations & Filings

Ticker · SUDEEPPHRM ISIN · INE0QPI01025 LEI · 335800ESH1W57DIPAN45 BSE.NS Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2026-02-02 Regulatory Filings
Country IN India
Listing BSE.NS SUDEEPPHRM

About Sudeep Pharma Limited

https://www.sudeeppharma.com/

Sudeep Pharma Limited specializes in the manufacturing of mineral-based excipients and active pharmaceutical ingredients (APIs). The company’s core portfolio includes high-purity mineral salts such as Calcium Phosphates, Calcium Carbonate, and Calcium Sulfate, which are utilized as essential components in solid dosage formulations and nutritional supplements. These products function as diluents, binders, and mineral sources across various applications. The organization maintains advanced production facilities compliant with international quality standards, including GMP, USP, EP, and BP. A strategic partnership with JRS Pharma enhances its technical expertise and global supply chain capabilities. Sudeep Pharma focuses on providing high-quality, regulatory-compliant mineral solutions to meet the demands of global markets, emphasizing research, development, and stringent quality control processes.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an upcoming Board Meeting scheduled for 6th February 2026. The purpose of the meeting includes considering and approving unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December 2025. The document also mentions the closure of the trading window in compliance with insider trading regulations. The document is short (2331 characters) and serves as an intimation or announcement rather than containing the actual financial results or detailed report. It does not contain financial statements or substantive financial data itself. Therefore, it is an announcement related to a board meeting and financial results, not the report itself. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-02-02 English
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for 6th February 2026. The purpose of the meeting includes considering and approving unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December 2025. The document also mentions the closure of the trading window in compliance with insider trading regulations. The content is an announcement of a Board Meeting and related procedural information, not the financial results report itself. The document length is short (2331 characters) and it does not contain actual financial data or detailed financial statements. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) notifying about the Board Meeting and upcoming financial results announcement.
2026-02-02 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the approval for purchase of rights in leasehold land by a wholly owned subsidiary of the company. It references compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, which pertains to disclosure of material events. The content includes detailed information about the transaction, parties involved, purpose, size, and other regulatory disclosure requirements. There is no financial data, earnings information, or report attached or referenced as being published. The document is a regulatory announcement about a material event (purchase of leasehold land rights) and is not a financial report, earnings release, or management discussion. This fits the category of Capital/Financing Update (CAP) as it relates to a significant capital asset acquisition by the company’s subsidiary, which impacts the company’s capital structure or asset base. The document length (6031 characters) and detailed disclosure align with a formal regulatory announcement under SEBI regulations about a capital transaction.
2026-01-22 English
We hereby inform you that the Company''s Wholly Owned Subsidiary i.e. Sudeep Advanced Materials Private Limited has purchased the rights in leasehold land in Dahej, Gujarat (GIDC) from ....
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the approval and disclosure of a transaction involving the purchase of rights in leasehold land by a wholly owned subsidiary of the company. It references compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, which governs material events and disclosures by listed companies. The content details the transaction specifics, parties involved, purpose, and other regulatory disclosure requirements. There is no financial report, earnings data, or management discussion present. The document is a regulatory announcement about a material event (purchase of leasehold land rights) and not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2026-01-22 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the change in the company's status and Corporate Identification Number (CIN) following its listing on these exchanges. It references compliance with SEBI Listing Regulations and provides updated company master data from the Ministry of Corporate Affairs (MCA) website. The document is short (3154 characters) and primarily serves as an announcement of the status update and listing, not a detailed financial report or other substantive filing. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement and compliance document category for filings that do not fit other specific categories.
2026-01-16 English
Intimation for update in Corporate Identification Number (CIN) and status of the Company on the MCA portal.
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the change in the company's status and Corporate Identification Number (CIN) following its listing on these exchanges. It references compliance with SEBI Listing Regulations and provides updated company master data from the Ministry of Corporate Affairs (MCA) website. The document is short (3154 characters) and primarily serves as an announcement of the status update and listing, not a detailed financial report or other substantive filing. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement and compliance document category for filings that do not fit other specific categories.
2026-01-16 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.